周剂量多西紫杉醇联合顺铂二线治疗进展期胃癌的临床研究

目的 研究多西紫杉醇(TXT)联合顺铂(DDP)方案二线治疗进展期胃癌的疗效和毒副作用.方法 既往应用FOLFOX4或XELOX方案化疗进展的晚期胃癌患者36例,采用多西紫杉醇(艾素)35 mg/m2,第1、8天,静滴;顺铂20 mg/m2,第1～5天,静滴,21 d为1个周期.结果 36例患者中,CR 0例,PR 10例,SD 12例,PD 14例,客观有效率(CR+PR)27.8%,中位生存期6.5个月,中位肿瘤进展时间4.4个月.毒副作用主要为中性粒细胞减少.结论 多西紫杉醇联合顺铂方案二线治疗进展期胃癌有效率较高,有生存优势,毒副作用可耐受.

The clinical study of weekly docetaxel combined with cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer

Objective To evaluate the efficacy and toxicity of docetaxel(TXT) plus cisplatin(DDP) for patients with metastatic or recurrent advanced gastric cancer(AGC), previously treated with FOLFOX4 or XELOX regimen. Methods Twenty-seyen patients were treated with docetaxel (35 mg/m2 on day 1 and 8)and cisplatin (20 mg/m2 on days 1 to 5) every 3 weeks. Results Of the 36 patients qualified for efficacy analysis,the overall response rate was 27. 8% , including 10 cases of PR, 12 cases of SD and 14 cases of PD respectively. The median time to progression was 4. 4 months and median survival time was 6. 5 months. The predominant toxicity was hematologic, with neutrop enia. Non-hematological toxicity was rarely severe. Conclusion Combination chemotherapy with TXT/DDP given on 2 out of 3 weeks is well tolerated and active in heavily pretreated patients with AGC, even after prior exposure to OXA and 5-FU.